Originally published May 7.

Over the past several years there has been a major shift in cancer diagnostics from systems based on physical and histological findings to methods that assess and treat tumors based on the presence of distinct, targetable genomic mutations. A primary example of this shift is lung cancer, a disease that was long viewed as monolithic and with few treatment options, but now is known to have many molecular subtypes and genetic tests that can match patients with those subtypes to treatments.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.